Effects of taking dacomitinib

The approval of Dacomitinib is based on a randomized, multicenter, open-label, active-controlled trial (ARCHER 1050) that compared the safety and efficacy of dacomitinib and gefitinib in 452 patients with unresectable, metastatic NSCLC. The trial showed a significant improvement in progression-free survival; there was no improvement in overall response rate or overall survival. Median progression-free survival as determined by an independent review committee. The dacomitinib group and gefitinib group were 14.7 months and 9.2 months respectively. A case series study of 14 patients showed that dacomitinib is also effective in central nervous system (CNS) metastasis of EGFR-positive non-small cell lung cancer. 56.3% of patients had confirmed partial response, 90.6% had disease control, median PFS was 10.3 months, and median OS was 36.5 months.